Cargando…

A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy

Epstein-Barr virus (EBV) linked with nasopharyngeal carcinoma (NPC) is considered to be one of the most prevalent head and neck malignancies in East and Southeast Asia. Although radiotherapy and chemotherapy are effective treatments for NPC, they have immunosuppressive effects. Immunotherapy has got...

Descripción completa

Detalles Bibliográficos
Autores principales: Bian, Jin, Niu, Yan, Ma, Yanli, Chen, Fuhua, Ma, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813251/
https://www.ncbi.nlm.nih.gov/pubmed/35126664
http://dx.doi.org/10.1155/2022/8537966
_version_ 1784644808259665920
author Bian, Jin
Niu, Yan
Ma, Yanli
Chen, Fuhua
Ma, Ning
author_facet Bian, Jin
Niu, Yan
Ma, Yanli
Chen, Fuhua
Ma, Ning
author_sort Bian, Jin
collection PubMed
description Epstein-Barr virus (EBV) linked with nasopharyngeal carcinoma (NPC) is considered to be one of the most prevalent head and neck malignancies in East and Southeast Asia. Although radiotherapy and chemotherapy are effective treatments for NPC, they have immunosuppressive effects. Immunotherapy has got considerable attention of clinicians for cancer treatment in recent years due to proven success of PD-1/PD-L 1 inhibition in solid tumors trials. The distinct immunological environment of EBV-associated NPC presents a reasonable therapeutic target for PD-1/PD-L 1 inhibition. Immune checkpoint blockade therapy targeting the programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L 1) receptors have shown efficacy in early phase I clinical trials, with ongoing phase III clinical trials. Herein, we have extensively addressed the role of the PD-1/PD-L1 axis in the immunotherapy of EBV-associated NPC. Immunotherapeutic strategies are anticipated to enter mainstream clinical practise and provide long-term remissions in patients with severe NPC.
format Online
Article
Text
id pubmed-8813251
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88132512022-02-04 A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy Bian, Jin Niu, Yan Ma, Yanli Chen, Fuhua Ma, Ning Appl Bionics Biomech Research Article Epstein-Barr virus (EBV) linked with nasopharyngeal carcinoma (NPC) is considered to be one of the most prevalent head and neck malignancies in East and Southeast Asia. Although radiotherapy and chemotherapy are effective treatments for NPC, they have immunosuppressive effects. Immunotherapy has got considerable attention of clinicians for cancer treatment in recent years due to proven success of PD-1/PD-L 1 inhibition in solid tumors trials. The distinct immunological environment of EBV-associated NPC presents a reasonable therapeutic target for PD-1/PD-L 1 inhibition. Immune checkpoint blockade therapy targeting the programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L 1) receptors have shown efficacy in early phase I clinical trials, with ongoing phase III clinical trials. Herein, we have extensively addressed the role of the PD-1/PD-L1 axis in the immunotherapy of EBV-associated NPC. Immunotherapeutic strategies are anticipated to enter mainstream clinical practise and provide long-term remissions in patients with severe NPC. Hindawi 2022-01-27 /pmc/articles/PMC8813251/ /pubmed/35126664 http://dx.doi.org/10.1155/2022/8537966 Text en Copyright © 2022 Jin Bian et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bian, Jin
Niu, Yan
Ma, Yanli
Chen, Fuhua
Ma, Ning
A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
title A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
title_full A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
title_fullStr A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
title_full_unstemmed A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
title_short A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
title_sort review on the application of pd-1 blockade in ebv-associated nasopharyngeal carcinoma immunotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813251/
https://www.ncbi.nlm.nih.gov/pubmed/35126664
http://dx.doi.org/10.1155/2022/8537966
work_keys_str_mv AT bianjin areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy
AT niuyan areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy
AT mayanli areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy
AT chenfuhua areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy
AT maning areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy
AT bianjin reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy
AT niuyan reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy
AT mayanli reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy
AT chenfuhua reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy
AT maning reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy